Microstructure of the non‐rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: Effects of dopaminergic treatment

Brunner, Hans; Wetter, Thomas C.; Högl, Birgit; Yassouridis, Alexander; Trenkwalder, Claudia; Frieß, Elisabeth

doi:10.1002/mds.10242

Cited by 91 publications

(89 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With cabergoline therapy, we found a trend towards increased stage 1 and stage 2 sleep. However, epoch assignment to conventional Rechtschaffen and Kales sleep stages has a limited reliability in PD (Bliwise et al, 2000), a drawback, that can possibly be resolved by more sophisticated forms of analyses (Brunner et al, 2002). When non-REM sleep stages one to four were summed up as has been proposed for PD (Bliwise et al, 2000), there was still no difference in the amount before and during cabergoline therapy.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Cabergoline on Sleep, Periodic Leg Movements in Sleep, and Early Morning Motor Function in Patients with Parkinson's Disease

Högl

Rothdach

Wetter

et al. 2003

Neuropsychopharmacol

Self Cite

View full text Add to dashboard Cite

To investigate the effect of the dopamine D2 and D1 receptor agonist cabergoline on sleep, periodic leg movements (PLMs) in sleep, and early morning motor performance in patients with Parkinson's disease (PD). It was hypothesized that cabergoline had long-lasting beneficial effects on sleep and PLMs in sleep in patients with PD, after a single evening intake. A total of 15 patients with idiopathic PD underwent two nights of polysomnography and motor tests (UPDRS, tapping test) before and after 6-8 weeks of treatment with cabergoline (dosage: 3-6 mg/day). Additionally, patients completed a subjective sleep visual analog scale (VAS) before and during cabergoline treatment. Compared to baseline values, treatment with cabergoline did not change sleep efficiency or the amount of stage 1 and stage 2 sleep. The number of awakenings (22.4 7 10.1 vs 32.5 7 13.3, po0.05) and stage shifts (119 7 42 vs 148 7 46, po0.05) were increased during treatment with cabergoline, and PLMs in sleep were reduced (PLM index 34.9 7 44.9 vs 6.7 7 4.2 per hour, po0.05). Cabergoline significantly improved early morning motor function, and in spite of increased phase shifts and awakenings, patients felt significantly more refreshed in the morning during cabergoline therapy. Cabergoline slightly fragmented sleep, without altering its total amount. The functional significance of this finding is uncertain. The subjective quality of sleep improved, and periodic limb movements in sleep decreased.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of Cabergoline on Sleep, Periodic Leg Movements in Sleep, and Early Morning Motor Function in Patients with Parkinson's Disease

Högl

Rothdach

Wetter

et al. 2003

Neuropsychopharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

“…77 Dopamine agonists increase the duration of stage I sleep and increase the number of awakenings. 78 Low-dose dopamine agonists have been associated with insomnia, whereas higher doses can cause EDS. 58 Selegiline can cause sleep initiation insomnia attributed to the stimulating effect of its amphetamine metabolite.…”

Section: Disorders Of Sleep Initiation and Maintenancementioning

confidence: 99%

Nonmotor manifestations of Parkinson's disease

2009

View full text Add to dashboard Cite

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease. Traditionally, attention has focused on the motor symptomatology of PD, but it is now appreciated that the nonmotor symptoms affecting neuropsychiatric, sleep, autonomic, and sensory domains occur in up to 88% of PD patients and can be an important source of disability. Nonmotor manifestations of PD play a significant role in the impairment of disease-related quality of life. The cause of nonmotor manifestations of PD is multifactorial, but to a large extent, these manifestations are related to the nature of the neurodegenerative process and the widespread nondopaminergic neuropathological changes associated with the disease. Recognition of nonmotor disability is essential not only for ascertaining the functional status of patients but also for better appreciating the nature of the neurodegenerative process in PD. In addition, a number of nonmotor manifestations can precede the onset of motor symptoms in PD and can be used as screening tools allowing for early disease identification and for trials of possible disease-modifying interventions. This article reviews depression, sleep, and autonomic dysfunction in PD.

show abstract

“…In agreement with the reported subjective sleep disturbances, previous polysomnographic studies showed that patients with Parkinson's disease exhibit significant abnormalities in sleep architecture not only in fully developed motor Parkinson's disease [12] but in the early phase of the disease as well. These abnormalities include increased sleep latency, reduced sleep efficiency, reduced rapid eye movement (REM) sleep [7], and significant changes in the REM and non-REM sleep architecture [13][14][15][16].…”

Section: Subjective Sleep Disturbances/ Insomniamentioning

confidence: 99%

Sleep-wake disturbances in the premotor and early stage of Parkinson's disease

Bargiotas

Schuepbach

Bassetti

2016

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of reviewReview of recent literature pertaining to frequency, associations, mechanisms, and overall significance of sleep-wake disturbances (SWD) in the premotor and early phase of Parkinson's disease.Recent findings SWD are frequent in Parkinson's disease and their prevalence increases with disease progression. Recent studies confirm previous findings that SWD can appear as initial manifestation of Parkinson's disease even decades before motor signs appear and highlight their clinical associations in these early stages. More intriguingly, new evidence underpins their role as risk factors, predictors, or even as driving force for the neurodegenerative process. As our understanding of sleep-wake neurobiology increases, new hypotheses emerge concerning the pathophysiology of SWD in early Parkinson's disease stages involving dopaminergic and nondopaminergic mechanisms. INTRODUCTIONSleep-wake disturbances (SWD) are frequent in Parkinson's disease and are typically attributed to Parkinson's disease medications, poor sleep hygiene, and other nonmotor symptoms (NMS) such as nocturnal akinesia, pain, cramping, and nycturia. Over the past decade, notable advances have been made in the understanding of the role of the dopaminergic system in circadian mechanisms and sleep-wake physiology [1]. In addition, nondopaminergic systems are involved early in the pathogenesis of SWD in Parkinson's disease [2,3]. These findings suggest that SWD are no longer solely a complication of advanced PD but can emerge, among other NMS, in the premotor stages as a primary manifestation of neurodegeneration [4] and increase in frequency with Parkinson's disease progression (Fig. 1). Considering the importance of early diagnosis and intervention, the possibility that SWD may have prognostic value for the development of Parkinson's disease is intriguing.This review will discuss first the most recent literature on SWD in the context of premotor and early stage of Parkinson's disease and then important recent evidence on the pathophysiology of SWD in early Parkinson's disease. SUBJECTIVE SLEEP DISTURBANCES/ INSOMNIATwo thirds of patients with Parkinson's disease report poor sleep quality [5], many of them very early in the course of the disease [6,7]. Recent studies confirm the high prevalence of subjective sleep disturbances in the early stages of Parkinson's disease and highlight their association with low quality of life [8,9&& ,10 && ] and other NMS such as global cognitive impairment, anxiety, depression and nocturia [8]. Individuals later diagnosed with

show abstract

Microstructure of the non‐rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: Effects of dopaminergic treatment

Cited by 91 publications

References 28 publications

The Effect of Cabergoline on Sleep, Periodic Leg Movements in Sleep, and Early Morning Motor Function in Patients with Parkinson's Disease

The Effect of Cabergoline on Sleep, Periodic Leg Movements in Sleep, and Early Morning Motor Function in Patients with Parkinson's Disease

Nonmotor manifestations of Parkinson's disease

Sleep-wake disturbances in the premotor and early stage of Parkinson's disease

Contact Info

Product

Resources

About